Pediatric thyroid hormone testing is a specialized clinical laboratory service that quantifies thyroid function markers such as TSH, FT4, FT3, and thyroid autoantibodies in newborns, infants, children, and adolescents. Accurate, age-stratified measurement is essential for the early detection of congenital hypothyroidism, autoimmune thyroid disease, and thyroid dysfunction that can impair growth and neurodevelopment. This technical guide covers sample types, tested analytes, analytical methods, quality standards, clinical applications, and frequently asked questions related to thyroid function testing in children.
Technical Overview
Thyroid hormones, principally thyroxine (T4) and triiodothyronine (T3), regulate basal metabolic rate, thermogenesis, skeletal maturation, and—most critically during infancy and early childhood—central nervous system development. The hypothalamic–pituitary–thyroid (HPT) axis controls hormone production through thyroid-stimulating hormone (TSH), making the TSH measurement the most sensitive first-line indicator of thyroid dysfunction in pediatric patients.
Pediatric thyroid hormone testing differs from adult testing in several important respects. First, reference intervals are strongly age-dependent: healthy neonates exhibit a physiological TSH surge within the first 24–48 hours of life, and total T4 levels are naturally elevated in infancy due to high thyroxine-binding globulin (TBG) concentrations before gradually declining toward adult values through childhood and puberty. Second, sample volumes are often limited in neonates and young children, requiring micro-volume analytical platforms. Third, the clinical consequences of delayed diagnosis are more severe, as untreated congenital hypothyroidism can lead to irreversible intellectual disability and growth failure.
Testing is performed by hospital clinical laboratories and accredited third-party laboratories operating under ISO 15189 medical laboratory quality management systems, with method-specific and age-specific pediatric reference intervals verified in accordance with recognized clinical laboratory standardization guidelines.
Testing Samples
Serum (Venous Blood)
Serum is the standard matrix for comprehensive thyroid function panels. A venous blood sample of approximately 0.5–2 mL is collected into a serum separator tube or plain tube, allowed to clot for 30 minutes at room temperature, and centrifuged to obtain clear serum. Gross hemolysis, severe lipemia, and microbial contamination should be avoided, as they can compromise immunoassay accuracy.
Dried Blood Spots (Newborn Screening)
For population-based congenital hypothyroidism screening, capillary blood is obtained by heel prick and applied to standardized filter paper cards. Samples are typically collected between 48 hours and 5 days of life, after the neonatal TSH surge has subsided, to minimize false-positive and false-negative results. Dried blood spot testing requires only a few drops of blood, making it ideal for large-scale neonatal screening programs.
Plasma
Sample Handling and Stability
- Fasting is not strictly required, but morning collection is recommended to account for the physiological diurnal variation of TSH.
- Serum samples are stable for 5–7 days at 2–8°C and for several months at –20°C or below.
- Repeated freeze–thaw cycles should be avoided to prevent protein degradation and analyte loss.
- Transport at refrigerated temperature with timely delivery to the laboratory is recommended for optimal result integrity.
Testing Items
A typical pediatric thyroid function workup includes a core panel of hormone analytes, which may be expanded with antibody and specialized markers depending on clinical indication:
- Thyroid-Stimulating Hormone (TSH): The most sensitive first-line marker; third-generation ultrasensitive assays with detection limits below 0.01–0.02 mIU/L are standard.
- Free T4 (FT4): The biologically active, unbound fraction of thyroxine; unaffected by TBG abnormalities and preferred over total T4 in most pediatric contexts.
- Total T4 (TT4): Useful in newborn screening algorithms and in evaluating TBG-binding disorders.
- Free T3 (FT3) and Total T3 (TT3): Indicated when hyperthyroidism is suspected or when T3-predominant disease must be excluded.
Extended Antibody and Specialized Panel
- Anti-Thyroid Peroxidase Antibodies (Anti-TPO): Primary marker of autoimmune thyroiditis (Hashimoto disease).
- Anti-Thyroglobulin Antibodies (Anti-Tg): Supplementary autoimmune marker, also relevant to thyroglobulin measurement validity.
- TSH Receptor Antibodies (TRAb): Diagnostic and prognostic marker for Graves disease and neonatal thyrotoxicosis risk assessment.
- Thyroglobulin (Tg): Used in differentiated thyroid carcinoma follow-up and congenital athyreosis evaluation.
- Reverse T3 (rT3): A specialized marker occasionally used in non-thyroidal illness syndrome investigations.
Testing Methods
Electrochemiluminescence Immunoassay (ECLIA)
ECLIA is the dominant methodology on modern automated platforms, offering wide dynamic range, excellent precision at low TSH concentrations, rapid throughput, and small sample volume requirements suited to pediatric specimens.
Chemiluminescent Immunoassay (CLIA)
CLIA provides comparable sensitivity and automation and is widely adopted in clinical laboratories for high-volume thyroid panels with turnaround times typically within 24 hours.
Enzyme-Linked Immunosorbent Assay (ELISA) and Time-Resolved Fluoroimmunoassay
ELISA and time-resolved fluorescence immunoassays are frequently used for dried blood spot newborn screening, enabling cost-effective processing of large neonatal sample batches.
Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
Quality Assurance and Interference Management
- Laboratories operate two-level internal quality controls with each analytical run and participate in external quality assessment schemes under ISO 15189 accreditation frameworks.
- High-dose biotin supplementation can cause clinically significant interference in streptavidin–biotin-based assays, producing falsely low TSH and falsely high FT4 results; medication disclosure is advised before testing.
- Heterophile antibodies, rheumatoid factor, and severe lipemia are documented interference sources that may require assay dilution, alternative platforms, or confirmatory LC-MS/MS testing.
Applications
Pediatric thyroid hormone testing supports a broad spectrum of clinical applications across neonatology, endocrinology, pediatrics, and child health surveillance programs:
- Newborn screening for congenital hypothyroidism: Population-based TSH-first or combined TSH/T4 strategies detect congenital hypothyroidism, with an incidence of approximately 1 in 2,000–4,000 live births, enabling levothyroxine initiation within the first two weeks of life.
- Diagnosis and monitoring of hypothyroidism: Serial TSH and FT4 measurements guide levothyroxine dose titration in children with congenital or acquired hypothyroidism.
- Diagnosis and management of hyperthyroidism: Suppressed TSH with elevated FT4/FT3, together with TRAb testing, confirms Graves disease and supports antithyroid drug monitoring.
- Autoimmune thyroid disease evaluation: Anti-TPO and Anti-Tg testing identifies Hashimoto thyroiditis in children with goiter or unexplained thyroid dysfunction.
- Growth and puberty disorders: Thyroid testing is a standard component of short stature, delayed growth, precocious puberty, and delayed puberty workups.
- High-risk population surveillance: Children with Down syndrome, Turner syndrome, type 1 diabetes mellitus, celiac disease, or a family history of thyroid disease benefit from periodic thyroid function screening.
- Goiter and thyroid nodule workup: Functional assessment complements imaging and cytology in structural thyroid disease evaluation.
FAQ
Why do children need thyroid hormone testing?
Thyroid hormones are indispensable for brain development and linear growth in childhood. Testing detects congenital and acquired thyroid dysfunction early—before developmental consequences occur—and monitors treatment effectiveness in children already receiving thyroid medication.
Do reference ranges differ between children and adults?
Yes. TSH, TT4, and FT4 concentrations vary significantly by age, particularly during the neonatal period and infancy. Laboratories must apply validated, age-specific pediatric reference intervals; interpreting a child's results against adult ranges can lead to erroneous conclusions.
Is fasting required before sample collection?
Fasting is not mandatory. However, morning collection is recommended because TSH follows a diurnal rhythm, and patients should avoid high-dose biotin supplements for at least 48–72 hours before testing to prevent immunoassay interference.
How much blood is required, and is the procedure safe for infants?
Automated immunoassay platforms require only 0.5–2 mL of blood for a complete panel, and newborn screening uses just a few drops from a heel prick. These volumes are well within safe limits for neonates and young children.
How quickly are results available?
Routine thyroid function panels are typically reported within 24–48 hours. Newborn screening programs generally deliver results within one to two weeks, with expedited reflex confirmatory testing initiated when the initial screen is abnormal.
What follow-up schedule is recommended for children on treatment?
Children receiving levothyroxine or antithyroid medications are usually monitored every 3–6 months, or more frequently during infancy, rapid growth phases, and dose adjustments, with measurement of TSH accompanied by FT4 as clinically indicated.
Which laboratories can perform reliable pediatric thyroid testing?
Reliable testing is available from hospital clinical laboratories and accredited third-party laboratories holding ISO 15189 accreditation, employing validated pediatric reference intervals, documented quality control procedures, and participation in recognized external quality assessment schemes.
